Dyadic's RSV, Malaria Antibodies Advance Into Preclinical Animal Studies

• Dyadic International’s C1-produced RSV and malaria antibodies entered preclinical animal studies led by the Gates Medical Research Institute.
• Studies began October 20, 2026, comparing RSM01 and MAM01 with conventional mammalian-cell-produced versions; results are expected in the first quarter of 2027.
• Positive independent laboratory evaluations supported advancement into animal testing; clinical development remains a potential next step.
• Successful results could strengthen the platform’s prospects as a lower-cost alternative for antibody manufacturing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyadic International Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120730PRIMZONEFULLFEED9876260) on November 12, 2026, and is solely responsible for the information contained therein.